Ocugen, Inc.

Ocugen, Inc.

0.76
USD
-0.02
(-2.11%)
-0.20EPS
349.49MMarket Cap
Mar 10Next Earn

Ocugen, Inc. Documents

Q4 FY2025 · Press release

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration · March 24, 2026 · 2 pages

Read Ocugen, Inc.'s results firsthand

Preview this press release
Create a free account to start reading

Full documents are included with Professional

Q4 FY2025 documents